Vor Biopharma
Vor Biopharma raises $110M Series C at $700M valuation
Vor Biopharma: Series C Funding Round
Vor Biopharma has successfully raised $110M in Series C funding, reaching a valuation of $700M.
Company Overview
Engineering hematopoietic stem cells
Funding Details
The Series C round was led by 5AM Ventures, with participation from Fidelity, SR One, Novartis Venture Fund, Cormorant Asset Management.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Vor Biopharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- 5AM Ventures: Verified investor in Series C
- Fidelity: Verified investor in Series C
- SR One: Verified investor in Series C
- Novartis Venture Fund: Verified investor in Series C
- Cormorant Asset Management: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free